Syros Pharmaceuticals (SYRS)

Company Profile

syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Company profile

Ticker

SYRS

Exchange

NASDAQ

Website

syros.com/

CEO

Nancy Simonian

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

Former names

LS22, Inc.

SEC CIK

0001556263

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Syros Securities Corporation • Syros Pharmaceuticals (Ireland) Limited • Tyme Technologies, Inc. • Tyme, Inc. ...

SYRS stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Termination of a Material Definitive Agreement

8 Aug 23

Termination of a Material Definitive Agreement

21 Jul 23

8-K

Submission of Matters to a Vote of Security Holders

2 Jun 23

8-K

Regulation FD Disclosure

10 May 23

Prospectus supplement for primary offering

1 May 23

EFFECT

Notice of effectiveness

1 May 23

CORRESP

Correspondence with SEC

26 Apr 23

ARS

2022 FY

Annual report to shareholders

21 Apr 23

Transcripts

View all

SYRS

Earnings call transcript

2023 Q2

8 Aug 23

SYRS

Earnings call transcript

2023 Q1

10 May 23

SYRS

Earnings call transcript

2022 Q4

2 Mar 23

SYRS

Earnings call transcript

2022 Q3

14 Nov 22

SYRS

Earnings call transcript

2022 Q2

9 Aug 22

SYRS

Earnings call transcript

2022 Q1

16 May 22

SYRS

Earnings call transcript

2021 Q4

15 Mar 22

SYRS

Earnings call transcript

2021 Q3

5 Nov 21

SYRS

Earnings call transcript

2021 Q2

8 Aug 21

SYRS

Earnings call transcript

2021 Q1

9 May 21

Latest ownership filings

View all

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart SYRS financial data

Quarter (USD)	Jun 23	Mar 23	Dec 22	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	118.53 mm	118.53 mm	118.53 mm	118.53 mm	118.53 mm	118.53 mm
Cash burn (monthly)	(no burn)	(no burn)	11.33 mm	11.89 mm	7.46 mm	10.51 mm
Cash used (since last report)	n/a	n/a	34.19 mm	35.87 mm	22.51 mm	31.72 mm
Cash remaining	n/a	n/a	84.33 mm	82.66 mm	96.01 mm	86.81 mm
Runway (months of cash)	n/a	n/a	7.4	7.0	12.9	8.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

SYRS institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	56	60	-6.7%
Opened positions	5	13	-61.5%
Closed positions	9	9	–
Increased positions	12	14	-14.3%
Reduced positions	6	10	-40.0%

13F shares	Current	Prev Q	Change
Total value	27.67 bn	17.09 bn	+61.9%
Total shares	15.60 mm	15.25 mm	+2.3%
Total puts	0.00	0.00
Total calls	80.60 k	80.00 k	+0.8%
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Bain Capital Life Sciences Investors	2.12 mm	$6.69 bn	0.0%
Bain Capital Life Sciences Fund II	2.12 mm	$0.00	0.0%
Artal	1.48 mm	$4.65 mm	0.0%
Avidity Partners Management	1.46 mm	$4.61 bn	+61.8%
Artal International S.C.A.	1.46 mm	$0.00	0.0%
Ally Bridge MedAlpha Master Fund	1.44 mm	$0.00	0.0%
Flagship Pioneering	993.85 k	$3.13 bn	0.0%
Samsara BioCapital	881.45 k	$2.78 bn	0.0%
CHI Advisors	767.45 k	$2.42 bn	0.0%
Adage Capital Partners GP, L.L.C.	721.91 k	$2.27 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
Avidity Partners Management	1.46 mm	+559.40 k	+61.8%
Ally Bridge	0.00	-249.13 k	EXIT
Knott David M Jr	96.26 k	+96.26 k	NEW
LGT Capital Partners	0.00	-55.00 k	EXIT
Geode Capital Management	129.86 k	+46.78 k	+56.3%
Marshall Wace	0.00	-30.55 k	EXIT
BLK Blackrock	211.06 k	+22.91 k	+12.2%
Susquehanna International	0.00	-19.63 k	EXIT
Clarius	0.00	-18.62 k	EXIT
Dimensional Fund Advisors	12.02 k	-18.21 k	-60.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SYRS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Sep 23	Akkaraju Srinivas	Common Stock	Option exercise	Acquire M	No	No	0	2,666	0.00	2,666
16 Sep 23	Akkaraju Srinivas	RSU Common Stock	Option exercise	Dispose M	No	No	0	2,666	0.00	5,334
16 Sep 23	Young Richard A	Common Stock	Option exercise	Acquire M	No	No	0	2,666	0.00	38,837
16 Sep 23	Young Richard A	RSU Common Stock	Option exercise	Dispose M	No	No	0	2,666	0.00	5,334
16 Sep 23	Alles Mark J	Common Stock	Option exercise	Acquire M	No	No	0	2,666	0.00	3,666
16 Sep 23	Alles Mark J	RSU Common Stock	Option exercise	Dispose M	No	No	0	2,666	0.00	5,334
12 Sep 23	Gerald E Quirk	RSU Common Stock	Grant	Acquire A	No	No	0	30,000	0.00	30,000
31 Jul 23	David Roth	Common Stock	Sell	Dispose S	No	Yes	3.95	7,348	29.02 k	0